Lexaria Bioscience (LEXX) 10-Q 14 Apr 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Feb. 28, 2021	Apr. 13, 2021
Cover [Abstract]
Entity Registrant Name	Lexaria Bioscience Corp.
Entity Central Index Key	0001348362
Current Fiscal Year End Date	--08-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		5,104,332
Document Type	10-Q
Document Period End Date	Feb. 28, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Current
Cash	$ 9,346,933	$ 1,293,749
Marketable securities (Note 19)	470,632	19,321
Accounts receivable (Note 7)	627,776	208,925
Inventory (Note 8)	137,282	116,871
Prepaid expenses and deposit (Note 18)	363,746	182,095
Current assets from discontinued operations (Note 20)	0	105,250
Total Current Assets	10,946,369	1,926,211
Non-current assets, net
Long term receivable (Note 7)	394,479
Lease right of use (Note 17)	109,306	126,920
Intellectual property (Note 9)	299,049	292,000
Property & equipment (Note 10)	423,205	483,357
Total Non-current Assets	1,226,039	902,277
TOTAL ASSETS	12,172,408	2,828,488
Current
Accounts payable and accrued liabilities (Note 11)	146,494	86,920
Deferred revenue	1,000	44,255
Due to a related parties (Note 15)	206,806	58,704
Loan payable	7,507
Lease payable (Note 17)	37,582	36,038
Current liabilities from discontinued operations (Note 20)	0	250
Total Current Liabilities	399,389	226,167
Long Term
Lease payable(Note 17)	70,156	89,393
Loan payable	0	30,670
Total Long Term Liabilities	70,156	120,063
TOTAL LIABILITIES	469,545	346,230
STOCKHOLDERS' EQUITY
Share Capital Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding:5,104,332 common shares at February 28, 2021 and 3,001,476 common shares at August 31, 2020 (Note 12)	5,104	3,001
Additional paid-in capital (Note 12)	39,859,831	30,324,398
Deficit	(28,094,115)	(27,802,198)
Equity attributable to shareholders of the Company	11,770,820	2,525,201
Non-Controlling Interest	(67,957)	(42,943)
Total Stockholders' Equity	11,702,863	2,482,258
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 12,172,408	$ 2,828,488

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Feb. 28, 2021	Aug. 31, 2020
Statement of Financial Position [Abstract]
Common stock, shares authorized	220,000,000	220,000,000
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares, Issued	5,104,332	3,001,476
Common Stock, Shares, Outstanding	5,104,332	3,001,476

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020
Income Statement [Abstract]
Revenue (Note 14)	$ 192,006	$ 37,549	$ 487,662	$ 99,631
Cost of goods sold	30,570	58,106	95,048	65,959
Gross profit	161,436	(20,557)	392,614	33,672
Expenses
Accounting and audit	42,282	7,493	57,910	26,529
Depreciation and amortization (Note 9, 10)	27,930	28,282	55,859	55,794
Advertising and promotions	56,867	33,903	84,773	80,171
Bad debt	25,000	0	37,000	0
Consulting (Notes 12, 13, 15)	435,786	521,228	691,800	1,005,024
Investor relations	44,187	3,762	78,151	21,277
Legal and professional	160,647	88,002	409,342	140,357
Office and miscellaneous	182,295	61,020	258,812	135,047
Research and development	176,398	186,557	368,659	294,020
Travel	318	21,087	850	42,940
Wages and salaries (Note 17)	72,161	90,768	147,659	178,361
(Gain) on disposal of assets (Note 20)	(1,522,704)	0	(1,522,704)	0
Unrealized (gain)/loss on marketable securities (Note 19)	41,362	(983)	16,952	40,591
Inventory writeoff (Note 8)	717	0	2,482	0
Total Operating Expenses	(256,754)	1,041,119	687,545	2,020,111
Net income (loss) from continuing operations	418,190	(1,061,676)	(294,931)	(1,986,439)
Discontinued operations
Income (loss) from discontinued operations (Note 20)	(25,000)	64,184	(22,000)	64,184
Net and comprehensive income (loss) for the period	393,190	(997,492)	(316,931)	(1,922,255)
Net and comprehensive income (loss) attributable to:
Common shareholders	404,111	(950,344)	(291,917)	(1,857,657)
Non-controlling interest	$ (10,921)	$ (47,148)	$ (25,014)	$ (64,598)
Basic and diluted income (loss) per share
Continuing operations	$ 0.10	$ (0.40)	$ (0.08)	$ (0.75)
Discontinued operations	(0.01)	0.02	(0.01)	0.02
Basic and diluted income (loss) per share (in dollars per share)	$ 0.09	$ (0.38)	$ (0.09)	$ (0.73)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	4,052,904	2,663,015	3,524,286	2,663,015

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020
Cash flows used in operating activities
Net loss from continuing operations	$ (294,931)	$ (1,986,439)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	66,041	456,707
Depreciation and amortization	55,859	55,794
Inventory write-off	2,482	0
Bad debt expense	37,000
Noncash right of use lease expense	17,614
Gain on disposal of assets	(1,522,704)
Unrealized loss on marketable securities	16,952	40,591
Warrants issued for services		70,752
Change in working capital
Accounts receivable	(69,264)	167,571
Inventory	(16,883)	3,108
Prepaid expenses and deposits	(181,651)	4,170
Accounts payable and accrued liabilities	59,574	(74,721)
Due to related parties	148,102	(46,496)
Operating lease liability	(17,693)
Deferred revenue	(43,255)
Net cash used in operating activities	(1,742,757)	(1,308,963)
Cash flows used in investing activities
Intellectual property	(8,766)	(5,711)
Disposal of Asset	273,375
Net cash used in investing activities	264,609	(5,711)
Cash flows from financing activities
Repayment of loan payable	(23,163)
Proceeds from issuance of equity	9,471,495	827,020
Net cash from financing Activities	9,448,332	827,020
Net cash from discontinued operations	83,000	(57,508)
Net Change in cash for the period	8,053,184	(545,162)
Cash at beginning of period	1,293,749	1,285,147
Cash at end of period	9,346,933	739,985
Supplemental information of cash flows:
Income taxes paid in cash	3,540	$ 957
Non-cash consideration on asset disposal	$ 1,171,599

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	DEFICIT	NCI	Total
Balance at Aug. 31, 2019	$ 2,626	$ 26,248,614	$ (23,868,202)	$ 107,674	$ 2,490,712
Balance (Shares) at Aug. 31, 2019	2,626,236
Stock based compensation		162,414			162,414
Warrants issued for services		70,752			70,752
Private Placement	$ 61	815,959			816,020
Private Placement (Shares)	60,792
Net loss			(907,313)		(907,313)
Non-controlling Interest				(17,450)	(17,450)
Balance at Nov. 30, 2019	$ 2,687	27,297,739	(24,775,515)	90,224	2,615,135
Balance (Shares) at Nov. 30, 2019	2,687,028
Balance at Aug. 31, 2019	$ 2,626	26,248,614	(23,868,202)	107,674	2,490,712
Balance (Shares) at Aug. 31, 2019	2,626,236
Net loss					(1,857,657)
Balance at Feb. 29, 2020	$ 2,691	27,603,028	(25,725,859)	43,076	1,922,936
Balance (Shares) at Feb. 29, 2020	2,690,695
Balance at Aug. 31, 2019	$ 2,626	26,248,614	(23,868,202)	107,674	$ 2,490,712
Balance (Shares) at Aug. 31, 2019	2,626,236
Exercise of stock options (in shares)					7,333
Balance at Aug. 31, 2020	$ 3,001	30,324,398	(27,802,198)	(42,943)	$ 2,482,258
Balance (Shares) at Aug. 31, 2020	3,001,476
Balance at Nov. 30, 2019	$ 2,687	27,297,739	(24,775,515)	90,224	2,615,135
Balance (Shares) at Nov. 30, 2019	2,687,028
Stock based compensation		294,293			294,293
Exercise of stock options	$ 4	10,996			11,000
Exercise of stock options (in shares)	3,667
Net loss			(950,344)		(950,344)
Non-controlling Interest				(47,148)	(47,148)
Balance at Feb. 29, 2020	$ 2,691	27,603,028	(25,725,859)	43,076	1,922,936
Balance (Shares) at Feb. 29, 2020	2,690,695
Stock based compensation		682,563			682,563
Warrants issued for services		98,081			98,081
Private Placement	$ 296	1,887,310			1,887,606
Private Placement (Shares)	295,540
Net loss			(1,361,381)		(1,361,381)
Non-controlling Interest				(29,272)	(29,272)
Balance at May. 31, 2020	$ 2,986	30,270,983	(27,087,240)	13,804	3,200,533
Balance (Shares) at May. 31, 2020	2,986,235
Exercise of stock options	$ 4	19,026			19,030
Exercise of stock options (in shares)	3,667
Shares issued for services	$ 12	99,988			100,000
Shares issued for services (Shares)	11,574
Private Placement		(65,600)			(65,600)
Net loss			(714,958)		(714,958)
Non-controlling Interest				(56,747)	(56,747)
Balance at Aug. 31, 2020	$ 3,001	30,324,398	(27,802,198)	(42,943)	2,482,258
Balance (Shares) at Aug. 31, 2020	3,001,476
Stock based compensation		48,887			48,887
Net loss			(696,028)		(696,028)
Non-controlling Interest				(14,093)	(14,093)
Balance at Nov. 30, 2020	$ 3,001	30,373,285	(28,498,226)	(57,036)	1,821,024
Balance (Shares) at Nov. 30, 2020	3,001,476
Balance at Aug. 31, 2020	$ 3,001	30,324,398	(27,802,198)	(42,943)	2,482,258
Balance (Shares) at Aug. 31, 2020	3,001,476
Net loss					(291,917)
Balance at Feb. 28, 2021	$ 5,104	39,859,831	(28,094,115)	(67,957)	11,702,863
Balance (Shares) at Feb. 28, 2021	5,104,332
Balance at Nov. 30, 2020	$ 3,001	30,373,285	(28,498,226)	(57,036)	1,821,024
Balance (Shares) at Nov. 30, 2020	3,001,476
Stock based compensation		17,154			17,154
Brokered placement	$ 2,103	9,469,392			9,471,495
Brokered placement (in shares)	2,102,856
Net loss			404,111		404,111
Non-controlling Interest				(10,921)	(10,921)
Balance at Feb. 28, 2021	$ 5,104	$ 39,859,831	$ (28,094,115)	$ (67,957)	$ 11,702,863
Balance (Shares) at Feb. 28, 2021	5,104,332

Organization, Business and Goin

Organization, Business and Going Concern	6 Months Ended
	Feb. 28, 2021
Organization, Business And Going Concern [Abstract]
Organization, Business and Going Concern	1. Organization, Business and Going Concern Lexaria Bioscience Corp. (“Lexaria”, or the “Company”) was formed on December 9, 2004 under the laws of the State of Nevada. In March of 2014, the Company began work in the fields of enhanced delivery of active ingredients and drugs. In May 2016, the Company commenced out-licensing its patented DehydraTECH™ technology (the “Technology”) for improved delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company has its office in Kelowna, BC, Canada. The Company’s unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (US GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated annual financial statements and notes thereto included in our annual report filed on Form 10-K for the year ended August 31, 2020. The Company’s unaudited interim consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has recurring losses from operations and net capital deficiency. On January 12, 2021 the Company closed an underwritten public offering for net proceeds of $9,471,495 (Note 12). The Company will require additional funds or revenues to maintain its operations and developments in the future. Management’s plans in this regard are to raise equity and debt financing as required, but there is no certainty that such financing will be available or that it will be available at acceptable terms in the future. The outcome of these matters cannot be predicted at this time. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments may adversely affect workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations at this time. During November of 2020, our Board of Directors ("Board") approved a plan to sell the businesses assets underlying our Canpharm THC related segment. As a result, the related financial results were reflected in our consolidated statement of operations, retrospectively, as discontinued operations beginning in the first quarter of fiscal 2021. On November 18, 2020, we signed a definitive agreement to sell the assets and the transaction was completed during December 2020. As a result, the related assets and liabilities associated with the discontinued operations in the prior year consolidated balance sheet are classified as discontinued operations. See "Note 20 - Discontinued Operations" for additional information.

Business Risk and Liquidity

Business Risk and Liquidity	6 Months Ended
	Feb. 28, 2021
Business Risk And Liquidity [Abstract]
Business Risk and Liquidity	2. Business Risk and Liquidity The Company is subject to several categories of risk associated with its operating activities. Although we intend to develop our businesses in accordance with best ethical practices, we may suffer negative publicity if we, our partners, contractors, or customers are found to have engaged in any environmentally insensitive practices or other business practices that are viewed as unethical. Our operations may require licenses and permits from various governmental authorities. We believe that we will be able to continue to obtain all necessary licenses and permits under applicable laws and regulations for our operations and believe we will be able to comply in all material respects with the terms of such licenses and permits. However, such licenses and permits are subject to change in various circumstances. There can be no guarantee that we will be able to obtain or maintain all necessary licenses and permits and failing to obtain or retain required licenses could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of cannabis or cannabis derived components. Lexaria does have an ancillary involvement risk via out-licensing of its patented technology to licensees that choose to utilize DehydraTECH to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the production or sale of any products containing nicotine. Products containing nicotine have historically been involved in litigation in the USA. Lexaria’s corporate licensee may introduce products containing nicotine that utilize DehydraTECH to the US consumer market, which could therefore introduce third-party risks to Lexaria. Lexaria and its subsidiaries are not involved directly or indirectly in the production or sale of any pharmaceutical or antiviral products. Licensees may enhance their product’s delivery using our Technology, which could therefore introduce third-party risks to Lexaria.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Feb. 28, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2020.

Basis of Consolidation

Basis of Consolidation	6 Months Ended
	Feb. 28, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Consolidation	4. Basis of Consolidation These interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria CanPharm ULC, PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp. and Lexaria Pharmaceutical Corp., and our 83.333% subsidiary Lexaria Nicotine LLC (16.667% Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc.). All significant intercompany balances and transactions have been eliminated.

Estimates and Judgments

Estimates and Judgments	6 Months Ended
	Feb. 28, 2021
Estimates And Judgments [Abstract]
Estimates and Judgments	5. Estimates and Judgements The preparation of financial statements in conformity with U.S GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations. The Company reviews these estimates, judgments and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, actual results could differ from these estimates. In preparing these unaudited interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the audited consolidated financial statements for the year ended August 31, 2020, aside from the following additions: Discontinued Operations Judgement is required in determining whether a subsidiary or group of assets qualifies as a business and as discontinued operations. A business is presumed to be an integrated set of activities and assets capable of being conducted and managed for the purpose of providing economic benefits. The Company determined that the assets sold were a business. The Company derecognizes a subsidiary or a group of assets only when the rights to the cash flows from the asset expire, or when it transfers the subsidiary or group of asset and substantially all the risks and rewards of ownership of the assets to another entity. Determination of the date of recognition was based on the closing date, final clearance, and approval by the TSX of the share issuances forming part of the consideration. As all consideration is in CDN$ and the share value is based on fixed CDN$ values, regardless of the share price of the underlying stock, the amounts were translated at the spot foreign exchange rate on the date of final closing. The valuation of the note receivable was included at its nominal value of $NIL as payment of the note is not determinable.

Recent Accounting Guidance

Recent Accounting Guidance	6 Months Ended
	Feb. 28, 2021
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Guidance	6. Recent Accounting Guidance In June 2016, the FASB issued a new standard to replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For trade and other receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available for sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2022. Application of the amendments is through a cumulative effect adjustment to deficit as of the effective date. The Company is currently assessing the impact of the standard on its consolidated financial statements.

Accounts and Other Receivables

Accounts and Other Receivables	6 Months Ended
	Feb. 28, 2021
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Accounts and Other Receivables	7. Accounts and Other Receivables February 28 August 31 2021 2020 $ $ Trade and deposits receivable 394,325 82,492 Intellectual property fees 160,760 38,250 Sales tax receivable 72,691 88,183 627,776 208,925 Short term trade and deposits receivable includes $390,533 of the current portion receivable from the asset sale (Note 20). $390,533 receivable related to the asset sale is also included in long term receivable as the payment is due greater than one year from February 28, 2021

Inventory

Inventory	6 Months Ended
	Feb. 28, 2021
Inventory Disclosure [Abstract]
Inventory	8. Inventory February 28 August 31 2021 2020 $ $ Raw materials 51,739 51,404 Work in progress 40,692 15,705 Finished goods 44,851 49,762 137,282 116,871 During the period ended February 28, 2021, the Company wrote down $2,482 (2020 - $8,240 full year) of inventory to reflect its net realisable value.

Intellectual Property

Intellectual Property	6 Months Ended
	Feb. 28, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	9. Intellectual Property The following is a list of US capitalized patents held by the Company Issued Patent # Patent Certificate Grant Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 US 10,756,180 08/25/2020 The Company also holds non-capitalized patents outside the US. A continuity schedule for capitalized patents is presented below: February 28 August 31 2021 2020 $ $ Balance – beginning 292,000 265,127 Addition 8,766 33,645 Amortization* (1,717 ) (6,772 ) Balance – ending 299,049 292,000 *The patents are amortized over their legal life of 20 years.

Property & Equipment

Property & Equipment	6 Months Ended
	Feb. 28, 2021
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Property & Equipment	10. Property & Equipment Six Months Ended February 28, 2021 Cost Period Amortization Disposal Accumulated Amortization Net Balance February 28, 2021 $ $ $ $ $ Leasehold improvements 259,981 (13,509 ) — (113,629 ) 146,352 Computers 63,964 (4,920 ) — (41,709 ) 22,255 Furniture fixtures equipment 34,220 (1,604 ) (3,094 ) (13,212 ) 17,914 Lab equipment 291,235 (9,116 ) — (54,551 ) 236,684 649,400 (29,150 ) (3,094 ) (223,101 ) 423,205 Year Ended August 31, 2020 Cost Period Amortization Accumulated Amortization Net Balance $ $ $ $ Leasehold improvements 259,981 (53,268 ) (86,610 ) 173,371 Computers 63,964 (19,681 ) (31,869 ) 32,095 Furniture fixtures equipment 34,220 (7,036 ) (13,097 ) 21,123 Lab equipment 291,235 (27,921 ) (34,467 ) 256,768 649,400 (107,906 ) (166,043 ) 483,357 During the six month period ended February 28, 2021, $6,010 of amortization was included in the cost of inventory.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	6 Months Ended
	Feb. 28, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	11. Accounts Payable and Accrued Liabilities February 28 August 31 2021 2020 $ $ Accounts Payable Trades payable 134,633 45,080 Accrued Liabilities Corporate tax payable 2,401 3,834 Trades payable 9,460 38,006 Balance 146,494 86,920

Common Shares and Warrants

Common Shares and Warrants	6 Months Ended
	Feb. 28, 2021
Equity [Abstract]
Common Shares and Warrants	12. Common Shares and Warrants During the quarter ended February 28, 2021 the Company issued the following shares and warrants summarized in the table presented below: Type of Issuance Number of Shares Total Value Placement (1) 2,102,856 $ 11,039,994 (1) A continuity schedule for warrants is presented below: Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2019 94,177 41.40 Cancelled/expired (25,000 ) 44.90 Issued 402,431 12.74 Balance August 31, 2020 471,608 16.77 Cancelled/expired (32,493 ) 67.50 Issued 2,330,017 6.58 Balance February 28, 2021 2,769,132 7.87 A summary of warrants outstanding as of is presented below: # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 3,334 0.23 years 28.80 8,334 0.24 years 46.50 25,000 0.61 years 4.20 292 0.71 years 36.00 7,500 1.68 years 24.00 51,814 3.71 years 36.00 8,984 3.75 years 36.00 16,667 4.05 years 9.00 267,618 4.19 years 10.50 49,572 4.20 years 10.50 2,330,017 4.88 years 6.58 2,769,132 4.70 years 7.87

Stock Options

Stock Options	6 Months Ended
	Feb. 28, 2021
Share-based Payment Arrangement [Abstract]
Stock Options	13. Stock Options The Company has established the 2014 Stock Option Plan whereby the board of directors may, from time to time, grant up to 62,917 stock options to directors, officers, employees, and consultants; and the 2019 Equity Incentive Plan whereby the board of directors may, from time to time, grant up to 261,290 stock options to directors, officers, employees, and consultants. Stock options granted must be exercised no later than five years from the date of grant or such lesser period as determined by the Company's board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company's common shares on the day preceding the date of grant. The vesting terms of each grant are set by the board of directors. The Company granted the following options during the quarter ended February 28, 2021: Quantity Exercise Price $ Life (Years) 3,400 4.80 5 A continuity schedule for stock options is presented below: Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2019 166,767 21.30 Cancelled/expired (149,437 ) 29.51 Exercised (7,333 ) 4.09 Granted 161,600 11.66 Balance August 31, 2020 171,604 11.17 Cancelled (2,000 ) 12.90 Granted 3,400 4.80 Balance February 28, 2021 (Outstanding) 173,004 11.03 3.82 30,812 Balance February 28, 2021 (Exercisable) 164,970 10.30 3.86 41,550 The fair value of share purchase options granted were estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: February 28 2021 Expected volatility 134 % Risk-free interest rate 0.42 % Expected life 5 years Dividend yield 0 % Estimated fair value per option $ 4.00

Revenues

Revenues	6 Months Ended
	Feb. 28, 2021
Revenues [Abstract]
Revenues	14. Revenues February 28 2021 $ February 29 2020 $ Product sales 231,718 99,191 Licensing revenue 255,844 — Freight revenue 100 440 Income from continuing operations 487,662 99,631 During the six months ended February 28, 2021, the Company recognized $255,844 of usage fees from continuing operations. Revenues are significantly concentrated on one customer. Our intermediate product sales significantly increased to $231,718 with licensees increasing their orders of our intermediate product. Intermediate products are typically a DehydraTECH enabled powder that companies can purchase to include in their products. Intermediate product sales and licensing revenue constituted the majority of our revenue. The licensing fees consist of intellectual property licensing fees for transfer of the Technology with the signing of definitive agreements for the DehydraTECH technology and usage fees.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Feb. 28, 2021
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Management, consulting and director services February 28, 2021 February 29, 2020 Contract Non Cash Total Contract Non Cash Total $ $ $ $ $ $ CAB Financial Services (1) 136,566 — 136,566 131,557 — 131,557 M&E Services Ltd. (1) 62,559 — 62,559 58,785 — 58,785 Docherty Management Limited (1) 124,987 — 124,987 113,569 187,069 300,638 Directors 37,533 13,612 51,145 35,214 — 35,214 361,645 13,612 375,257 339,125 187,069 526,194 (1) All related party transactions pertain to management and director agreements entered into in the normal course of business (Note 17). Due to related parties Related party transactions are recorded at the exchange amount established and agreed to between the related parties. As at February 28, 2021, $206,806 (August 31, 2020 - $58,704) was payable to related parties and included in due to related parties.

Segment Information

Segment Information	6 Months Ended
	Feb. 28, 2021
Segment Reporting [Abstract]
Segment Information	16. Segment Information The Company's operations involve the development and usage, including licensing, of its proprietary DehydraTECH Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property and Products. Licensing revenues are significantly concentrated on one licensee. IP Licensing $ Products $ Corporate $ Consolidated Total $ Revenue 255,844 231,818 — 487,662 Cost of goods sold — (95,048 ) — (95,048 ) Operating expenses 1,142,518 (278,374 ) (1,551,689 ) (687,545 ) Discontinued operations (22,000 ) — — (22,000 ) Segment income(loss) 1,376,362 (141,604 ) (1,551,689 ) (316,931 ) Total assets 696,493 137,282 11,338,633 12,172,408 Capital Asset by Region Cost Disposal US Net Balance Cost Net Balance Canada Total Net Balance Six Months Ended February 28, 2021 $ $ $ $ $ $ Leasehold Improvements — — — 259,981 146,352 146,352 Computers — — — 63,964 22,255 22,255 Furniture Fixtures Equipment 3,094 3,094 — 31,126 17,914 17,914 Lab Equipment 98,050 — 74,843 193,185 161,841 236,684 101,144 3,094 74,843 548,256 348,362 423,205 Capital Asset by Region Cost Net Balance Cost Net Balance Canada Total Net Balance Year Ended August 31, 2020 $ $ $ $ $ Leasehold Improvements — — 259,981 173,371 173,371 Computers — — 63,964 32,095 32,095 Furniture Fixtures Equipment 3,094 — 31,126 21,123 21,123 Lab Equipment 98,050 85,263 193,185 171,505 256,768 101,144 85,263 548,256 398,094 483,357

Commitments, Significant Contra

Commitments, Significant Contracts and Contingencies	6 Months Ended
	Feb. 28, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments, Significant Contracts and Contingencies	17. Commitments, Significant Contracts and Contingencies Management and Service Agreements: As at February 28, 2021, the Company is party to the following contractual commitments: Party Monthly Commitment Expiry Date C.A.B Financial Services CAD $29,706 January 1, 2022 Docherty Management Ltd. CAD $25,609 January 1, 2022 M&E Services Ltd. CAD $13,997 June 1, 2021 Office Management CAD $10,800 August 15, 2022 Research & Development CAD $3,854 Month to Month Office operating lease (1) CAD $4,823 November 15, 2023 Right of Use Assets - Operating Lease (1) Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments. Right of use assets - operating leases: $ Additions 118,193 Amortization (8,887 ) Total right of use assets (February 28, 2021) 109,306 Liabilities: Additions 116,664 Lease payments (10,987 ) Interest accretion 2,061 Total lease liabilities (February 28, 2021) 107,738 Operating lease cost as at February 28, 2021 Operating cash flows for lease 10,948 Remaining lease term 2.5 Years Discount rate 7.25 % Pursuant to the terms of the Company's lease agreements in effect, the following table summarizes the Company's maturities of operating lease liabilities as of February 28, 2021: 2021 21,975 2022 44,599 2023 44,815 2024 7,469 Thereafter — Total lease payments 118,857 Less: imputed interest (11,119 ) Present value of operating lease liabilities 107,737 Less: current obligations under leases (37,582 ) Total 70,156

Prepaid Expenses

Prepaid Expenses	6 Months Ended
	Feb. 28, 2021
Prepaid Expense, Current [Abstract]
Prepaid Expenses	18. Prepaid Expenses February 28 August 31 2021 2020 $ $ Advertising & conferences 170,165 21,878 Investor relations 71,667 — Legal fees — 47,498 Licence, filing fees, dues 59,967 8,541 Office & insurance 36,561 78,792 Research & development 25,386 25,386 363,746 182,095

Marketable Securities

Marketable Securities	6 Months Ended
	Feb. 28, 2021
Marketable Securities [Abstract]
Marketable Securities	19. Marketable Securities The components of Marketable Securities were as follows: Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2020 Common stock 56,250 9,997 (38,584 ) Total 56,250 9,997 (46,926 ) 19,321 February 28, 2021 Common stock 524,513 24,410 (41,362 ) Total 524,513 34,407 (88,288 ) 470,632 During the period ended February 28, 2021, the Company added $468,263 in marketable securities as a component of the sale of assets (Note 20). Unrealized gains and losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence. The COVID-19 pandemic has caused significant market turbulence and it is possible that our evaluation will change dependent upon new information as it arises.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Feb. 28, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	20. Discontinued Operations On November 19, 2020 the Company entered a definitive asset sale agreement through its wholly owned subsidiary Lexaria Canpharm ULC to sell certain non-core business assets for gross proceeds of C$3,850,000. On December 10, 2020 the sale closed. The Company received from Hill Street Beverage Company C$350,000 in cash, 6,031,363 restricted common shares at a deemed price of C$0.0829 per share as the first required equity-based payment, a promissory note having a principal amount of C$2,000,000 and bearing interest at the rate of 10% per annum. Pursuant to the terms of the transaction, the Company will receive another C$1,000,000 worth of common shares over a period sixteen months in C$500,000 issuances eight months and sixteen months after the closing date. The C$ were converted at the spot rate of 0.78107 at the closing date. The promissory note was included at its nominal value of $ NIL Gain on asset disposal $ Book value of assets sold — Cash consideration 273,373 Shares received 468,264 Shares receivable 781,067 Promissory note — 1,522,704 The financial results of the group of assets sold are presented as income (loss) from discontinued operations, net of income taxes in our consolidated statement of income. The following table presents financial results of the assets: SIX MONTHS ENDED February 28 February 29 2021 2020 Revenue $ 3,000 $ 69,750 Operating Expenses 25,000 5,566 Net Income $ (22,000 ) $ 64,184 The following table presents cash flows of discontinued operations: SIX MONTHS ENDED February 28 February 29 2021 2020 Cash flows used in discontinued operating activities Net income $ (22,000 ) $ 64,184 Change in working capital 105,000 (99,000 ) Net cash provided by (used in) discontinued operating activities $ 83,000 $ (34,816 ) Net cash provided by (used in) discontinued operations 83,000 $ (34,816 ) The following table presents the aggregate carrying amounts of the classes of assets and liabilities of discontinued operations of the assets: February 28 August 31 2021 2020 Current Assets Accounts receivable $ — $ 105,250 Total assets classified as discontinued operations in the consolidated balance sheet — 105,250 Current Liabilities Accounts payable $ — $ 250 Total liabilities classified as discontinued operations in the consolidated balance sheet — 250

Accounts and Other Receivables

Accounts and Other Receivables (Tables)	6 Months Ended
	Feb. 28, 2021
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Schedule of accounts and other receivables	February 28 August 31 2021 2020 $ $ Trade and deposits receivable 394,325 82,492 Intellectual property fees 160,760 38,250 Sales tax receivable 72,691 88,183 627,776 208,925

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Feb. 28, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	February 28 August 31 2021 2020 $ $ Raw materials 51,739 51,404 Work in progress 40,692 15,705 Finished goods 44,851 49,762 137,282 116,871

Intellectual Property (Tables)

Intellectual Property (Tables)	6 Months Ended
	Feb. 28, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of patents	February 28 August 31 2021 2020 $ $ Balance – beginning 292,000 265,127 Addition 8,766 33,645 Amortization* (1,717 ) (6,772 ) Balance – ending 299,049 292,000 *The patents are amortized over their legal life of 20 years.

Property & Equipment (Tables)

Property & Equipment (Tables)	6 Months Ended
	Feb. 28, 2021
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Schedule of property & equipment	Six Months Ended February 28, 2021 Cost Period Amortization Disposal Accumulated Amortization Net Balance February 28, 2021 $ $ $ $ $ Leasehold improvements 259,981 (13,509 ) — (113,629 ) 146,352 Computers 63,964 (4,920 ) — (41,709 ) 22,255 Furniture fixtures equipment 34,220 (1,604 ) (3,094 ) (13,212 ) 17,914 Lab equipment 291,235 (9,116 ) — (54,551 ) 236,684 649,400 (29,150 ) (3,094 ) (223,101 ) 423,205 Year Ended August 31, 2020 Cost Period Amortization Accumulated Amortization Net Balance $ $ $ $ Leasehold improvements 259,981 (53,268 ) (86,610 ) 173,371 Computers 63,964 (19,681 ) (31,869 ) 32,095 Furniture fixtures equipment 34,220 (7,036 ) (13,097 ) 21,123 Lab equipment 291,235 (27,921 ) (34,467 ) 256,768 649,400 (107,906 ) (166,043 ) 483,357

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Feb. 28, 2021
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities	February 28 August 31 2021 2020 $ $ Accounts Payable Trades payable 134,633 45,080 Accrued Liabilities Corporate tax payable 2,401 3,834 Trades payable 9,460 38,006 Balance 146,494 86,920

Common Shares and Warrants (Tab

Common Shares and Warrants (Tables)	6 Months Ended
	Feb. 28, 2021
Equity [Abstract]
Schedule of shares and warrants issued	Type of Issuance Number of Shares Total Value Placement (1) 2,102,856 $ 11,039,994 (1)
Schedule of warrant	Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2019 94,177 41.40 Cancelled/expired (25,000 ) 44.90 Issued 402,431 12.74 Balance August 31, 2020 471,608 16.77 Cancelled/expired (32,493 ) 67.50 Issued 2,330,017 6.58 Balance February 28, 2021 2,769,132 7.87
Schedule of warrants outstanding	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 3,334 0.23 years 28.80 8,334 0.24 years 46.50 25,000 0.61 years 4.20 292 0.71 years 36.00 7,500 1.68 years 24.00 51,814 3.71 years 36.00 8,984 3.75 years 36.00 16,667 4.05 years 9.00 267,618 4.19 years 10.50 49,572 4.20 years 10.50 2,330,017 4.88 years 6.58 2,769,132 4.70 years 7.87

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended
	Feb. 28, 2021
Share-based Payment Arrangement [Abstract]
Schedule of exercise price	Quantity Exercise Price $ Life (Years) 3,400 4.80 5
Schedule of stock options	Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2019 166,767 21.30 Cancelled/expired (149,437 ) 29.51 Exercised (7,333 ) 4.09 Granted 161,600 11.66 Balance August 31, 2020 171,604 11.17 Cancelled (2,000 ) 12.90 Granted 3,400 4.80 Balance February 28, 2021 (Outstanding) 173,004 11.03 3.82 30,812 Balance February 28, 2021 (Exercisable) 164,970 10.30 3.86 41,550
Schedule of fair value of options granted	February 28 2021 Expected volatility 134 % Risk-free interest rate 0.42 % Expected life 5 years Dividend yield 0 % Estimated fair value per option $ 4.00

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Feb. 28, 2021
Revenues [Abstract]
Schedule of revenue	February 28 2021 $ February 29 2020 $ Product sales 231,718 99,191 Licensing revenue 255,844 — Freight revenue 100 440 Income from continuing operations 487,662 99,631

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Feb. 28, 2021
Related Party Transactions [Abstract]
Schedule of related party transactions	Management, consulting and director services February 28, 2021 February 29, 2020 Contract Non Cash Total Contract Non Cash Total $ $ $ $ $ $ CAB Financial Services (1) 136,566 — 136,566 131,557 — 131,557 M&E Services Ltd. (1) 62,559 — 62,559 58,785 — 58,785 Docherty Management Limited (1) 124,987 — 124,987 113,569 187,069 300,638 Directors 37,533 13,612 51,145 35,214 — 35,214 361,645 13,612 375,257 339,125 187,069 526,194 (1)

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Feb. 28, 2021
Segment Reporting [Abstract]
Schedule of the profit or loss and total assets for each reportable segment	IP Licensing $ Products $ Corporate $ Consolidated Total $ Revenue 255,844 231,818 — 487,662 Cost of goods sold — (95,048 ) — (95,048 ) Operating expenses 1,142,518 (278,374 ) (1,551,689 ) (687,545 ) Discontinued operations (22,000 ) — — (22,000 ) Segment income(loss) 1,376,362 (141,604 ) (1,551,689 ) (316,931 ) Total assets 696,493 137,282 11,338,633 12,172,408
Schedule of capital asset by region	Capital Asset by Region Cost Disposal US Net Balance Cost Net Balance Canada Total Net Balance Six Months Ended February 28, 2021 $ $ $ $ $ $ Leasehold Improvements — — — 259,981 146,352 146,352 Computers — — — 63,964 22,255 22,255 Furniture Fixtures Equipment 3,094 3,094 — 31,126 17,914 17,914 Lab Equipment 98,050 — 74,843 193,185 161,841 236,684 101,144 3,094 74,843 548,256 348,362 423,205 Capital Asset by Region Cost Net Balance Cost Net Balance Canada Total Net Balance Year Ended August 31, 2020 $ $ $ $ $ Leasehold Improvements — — 259,981 173,371 173,371 Computers — — 63,964 32,095 32,095 Furniture Fixtures Equipment 3,094 — 31,126 21,123 21,123 Lab Equipment 98,050 85,263 193,185 171,505 256,768 101,144 85,263 548,256 398,094 483,357

Commitments, Significant Cont_2

Commitments, Significant Contracts and Contingencies (Tables)	6 Months Ended
	Feb. 28, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of management and service agreements	Party Monthly Commitment Expiry Date C.A.B Financial Services CAD $29,706 January 1, 2022 Docherty Management Ltd. CAD $25,609 January 1, 2022 M&E Services Ltd. CAD $13,997 June 1, 2021 Office Management CAD $10,800 August 15, 2022 Research & Development CAD $3,854 Month to Month Office operating lease (1) CAD $4,823 November 15, 2023 Right of Use Assets - Operating Lease (1) Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments.
Schedule of information about operating lease	Right of use assets - operating leases: $ Additions 118,193 Amortization (8,887 ) Total right of use assets (February 28, 2021) 109,306 Liabilities: Additions 116,664 Lease payments (10,987 ) Interest accretion 2,061 Total lease liabilities (February 28, 2021) 107,738 Operating lease cost as at February 28, 2021 Operating cash flows for lease 10,948 Remaining lease term 2.5 Years Discount rate 7.25 %
Schedule of maturities of operating lease liabilities	2021 21,975 2022 44,599 2023 44,815 2024 7,469 Thereafter — Total lease payments 118,857 Less: imputed interest (11,119 ) Present value of operating lease liabilities 107,737 Less: current obligations under leases (37,582 ) Total 70,156

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	6 Months Ended
	Feb. 28, 2021
Prepaid Expense, Current [Abstract]
Schedule of prepaid expenses	February 28 August 31 2021 2020 $ $ Advertising & conferences 170,165 21,878 Investor relations 71,667 — Legal fees — 47,498 Licence, filing fees, dues 59,967 8,541 Office & insurance 36,561 78,792 Research & development 25,386 25,386 363,746 182,095

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Feb. 28, 2021
Marketable Securities [Abstract]
Schedule of marketable securities	Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2020 Common stock 56,250 9,997 (38,584 ) Total 56,250 9,997 (46,926 ) 19,321 February 28, 2021 Common stock 524,513 24,410 (41,362 ) Total 524,513 34,407 (88,288 ) 470,632

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Feb. 28, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of gain on asset disposal	Gain on asset disposal $ Book value of assets sold — Cash consideration 273,373 Shares received 468,264 Shares receivable 781,067 Promissory note — 1,522,704
Schedule of discontinued operations	The financial results of the group of assets sold are presented as income (loss) from discontinued operations, net of income taxes in our consolidated statement of income. The following table presents financial results of the assets: SIX MONTHS ENDED February 28 February 29 2021 2020 Revenue $ 3,000 $ 69,750 Operating Expenses 25,000 5,566 Net Income $ (22,000 ) $ 64,184 The following table presents cash flows of discontinued operations: SIX MONTHS ENDED February 28 February 29 2021 2020 Cash flows used in discontinued operating activities Net income $ (22,000 ) $ 64,184 Change in working capital 105,000 (99,000 ) Net cash provided by (used in) discontinued operating activities $ 83,000 $ (34,816 ) Net cash provided by (used in) discontinued operations 83,000 $ (34,816 ) The following table presents the aggregate carrying amounts of the classes of assets and liabilities of discontinued operations of the assets: February 28 August 31 2021 2020 Current Assets Accounts receivable $ — $ 105,250 Total assets classified as discontinued operations in the consolidated balance sheet — 105,250 Current Liabilities Accounts payable $ — $ 250 Total liabilities classified as discontinued operations in the consolidated balance sheet — 250

Organization, Business and Go_2

Organization, Business and Going Concern (Detail Textuals)	Jan. 11, 2021
Organization, Business And Going Concern [Abstract]
Description, reverse stock split	30:1

Basis of Consolidation (Detail

Basis of Consolidation (Detail Textuals)	Feb. 28, 2021
Lexaria Nicotine LLC
Equity interest percentage	83.333%
Altria Ventures Inc.
Equity interest percentage	16.667%

Accounts and Other Receivable_2

Accounts and Other Receivables (Details) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Trade and deposits receivable	$ 394,325	$ 82,492
Intellectual Property Fees	160,760	38,250
Sales tax receivable	72,691	88,183
Accounts and other receivable	$ 627,776	$ 208,925

Accounts and Other Receivable_3

Accounts and Other Receivables (Detail Textuals)	Feb. 28, 2021USD ($)
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Current portion of trade and deposits receivable	$ 390,533
Non current portion of trade and deposits receivable	$ 390,533

Inventory (Details)

Inventory (Details) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 51,739	$ 51,404
Work in progress	40,692	15,705
Finished goods	44,851	49,762
Inventory	$ 137,282	$ 116,871

Inventory (Detail Textuals)

Inventory (Detail Textuals) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020	Aug. 31, 2020
Inventory Disclosure [Abstract]
Inventory write-off	$ 717	$ 0	$ 2,482	$ 0	$ 8,240

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)		6 Months Ended	12 Months Ended
		Feb. 28, 2021	Aug. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Balance - beginning		$ 292,000	$ 265,127
Addition		8,766	33,645
Amortization	[1]	(1,717)	(6,772)
Balance - ending		$ 299,049	$ 292,000
[1]	The patents are amortized over their legal life of 20 years.

Intellectual Property (Detail T

Intellectual Property (Detail Textuals)	6 Months Ended
	Feb. 28, 2021
Alternative Health Products [Line Items]
Useful life	20 years

Property & Equipment (Details)

Property & Equipment (Details) - USD ($)	6 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Equipment	$ 649,400	$ 649,400
Less accumulated amortization	(223,101)	(166,043)
Disposal	(3,094)
Balance - Ending	423,205	483,357
Period Amortization
Less accumulated amortization	(29,150)	(107,906)
Leasehold improvements
Equipment	259,981	259,981
Less accumulated amortization	(113,629)	(86,610)
Disposal	0
Balance - Ending	146,352	173,371
Leasehold improvements | Period Amortization
Less accumulated amortization	(13,509)	(53,268)
Computers
Equipment	63,964	63,964
Less accumulated amortization	(41,709)	(31,869)
Disposal	0
Balance - Ending	22,255	32,095
Computers | Period Amortization
Less accumulated amortization	(4,920)	(19,681)
Furniture fixtures equipment
Equipment	34,220	34,220
Less accumulated amortization	(13,212)	(13,097)
Disposal	(3,094)
Balance - Ending	17,914	21,123
Furniture fixtures equipment | Period Amortization
Less accumulated amortization	(1,604)	(7,036)
Lab equipment
Equipment	291,235	291,235
Less accumulated amortization	(54,551)	(34,467)
Disposal	0
Balance - Ending	236,684	256,768
Lab equipment | Period Amortization
Less accumulated amortization	$ (9,116)	$ (27,921)

Property & Equipment (Detail Te

Property & Equipment (Detail Textuals)	6 Months Ended
	Feb. 28, 2021USD ($)
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Amortization cost	$ 6,010

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Accounts Payable And Accrued Liabilities[Line Items]
Balance - ending	$ 146,494	$ 86,920
Accounts Payable
Accounts Payable And Accrued Liabilities[Line Items]
Trades payable	134,633	45,080
Accrued Liabilities
Accounts Payable And Accrued Liabilities[Line Items]
Corporate tax payable	2,401	3,834
Trades payable	$ 9,460	$ 38,006

Common Shares and Warrants (Det

Common Shares and Warrants (Details) - Common stock - USD ($)		3 Months Ended		6 Months Ended
		May 31, 2020	Nov. 30, 2019	Feb. 28, 2021
Class of Stock [Line Items]
Number of Shares		295,540	60,792
Placement
Class of Stock [Line Items]
Number of Shares	[1]			2,102,856
Total Value	[1]			$ 11,039,994
[1]	Total fees of $1,568,499 were paid for total net receipt of $9,471,495

Common Shares and Warrants (Par

Common Shares and Warrants (Parentheticals) (Details)	6 Months Ended
	Feb. 28, 2021USD ($)
Equity [Abstract]
Payments of Stock Issuance Costs	$ 1,568,499
Proceeds from Issuance of Common Stock	$ 9,471,495

Common Shares and Warrants (D_2

Common Shares and Warrants (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Common Shares And Warrants [Roll Forward]
Number of Warrants, Balance	471,608	94,177
Weighted Average Exercise Price, Balance	$ 16.77	$ 41.40
Number of Warrants, Cancelled/expired	(32,493)	(25,000)
Weighted Average Exercise Price, Cancelled Expired	$ 67.50	$ 44.90
Number of Warrants, Issued	2,330,017	402,431
Weighted Average Exercise Price, Issued	$ 6.58	$ 12.74
Number of Warrants, Balance	2,769,132	471,608
Weighted Average Exercise Price, Balance	$ 7.87	$ 16.77

Common Shares and Warrants (D_3

Common Shares and Warrants (Details 2) - $ / shares	6 Months Ended
	Feb. 28, 2021	Aug. 31, 2020	Aug. 31, 2019
Number of Warrants	2,769,132	471,608	94,177
Weighted Average Remaining Contractual Life	4 years 8 months 12 days
Weighted Average Exercise Price	$ 7.87
# of Warrants 3,334
Number of Warrants	3,334
Weighted Average Remaining Contractual Life	2 months 23 days
Weighted Average Exercise Price	$ 28.80
# of Warrants 8,334
Number of Warrants	8,334
Weighted Average Remaining Contractual Life	2 months 26 days
Weighted Average Exercise Price	$ 46.50
# of Warrants 25,000
Number of Warrants	25,000
Weighted Average Remaining Contractual Life	7 months 9 days
Weighted Average Exercise Price	$ 4.20
# of Warrants 292
Number of Warrants	292
Weighted Average Remaining Contractual Life	8 months 15 days
Weighted Average Exercise Price	$ 36
# of Warrants 7,500
Number of Warrants	7,500
Weighted Average Remaining Contractual Life	1 year 8 months 4 days
Weighted Average Exercise Price	$ 24
# of Warrants 51,814
Number of Warrants	51,814
Weighted Average Remaining Contractual Life	3 years 8 months 15 days
Weighted Average Exercise Price	$ 36
# of Warrants 8,984
Number of Warrants	8,984
Weighted Average Remaining Contractual Life	3 years 9 months
Weighted Average Exercise Price	$ 36
# of Warrants 16,667
Number of Warrants	16,667
Weighted Average Remaining Contractual Life	4 years 18 days
Weighted Average Exercise Price	$ 9
# of Warrants 267,618
Number of Warrants	267,618
Weighted Average Remaining Contractual Life	4 years 2 months 8 days
Weighted Average Exercise Price	$ 10.50
# of Warrants 49,572
Number of Warrants	49,572
Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Weighted Average Exercise Price	$ 10.50
# of Warrants 2,330,017
Number of Warrants	2,330,017
Weighted Average Remaining Contractual Life	4 years 10 months 17 days
Weighted Average Exercise Price	$ 6.58

Stock Options (Details)

Stock Options (Details) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Option Indexed to Issuer's Equity [Line Items]
Exercise price	$ 4.80	$ 11.66
Stock Options 1
Option Indexed to Issuer's Equity [Line Items]
Quantity	3,400
Exercise price	$ 4.80
Life (Years)	5 years

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Options
Balance, Outstanding	171,604	166,767
Cancelled/expired	(2,000)	(149,437)
Exercised		(7,333)
Granted	3,400	161,600
Balance, Outstanding	173,004	171,604
Balance, Exercisable	164,970
Weighted Average Exercise Price
Balance, Outstanding	$ 11.17	$ 21.30
Cancelled/expired	12.90	29.51
Exercise Price		4.09
Granted	4.80	11.66
Balance, Outstanding	11.03	$ 11.17
Balance, Exercisable	$ 10.30
Weighted Average Remaining Contractual Term, Outstanding (Years)	3 years 9 months 25 days
Weighted Average Remaining Contractual Term, Exercisable (Years)	3 years 10 months 9 days
Aggregate Intrinsic Value, Outstanding	$ 30,812
Aggregate Intrinsic Value, Exercisable	$ 41,550

Stock Options (Details 2)

Stock Options (Details 2)	6 Months Ended
	Feb. 28, 2021$ / shares
Share-based Payment Arrangement [Abstract]
Expected volatility	134.00%
Risk-free interest rate	0.42%
Expected life	5 years
Dividend yield	0.00%
Estimated fair value per option	$ 4

Stock Options (Detail Textuals)

Stock Options (Detail Textuals)	6 Months Ended
	Feb. 28, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of expiration	5 years
2019 Equity Incentive Plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	261,290
2014 Stock Option Plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	62,917

Revenues (Details)

Revenues (Details) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020
Revenue [Line Items]
Income from continuing operations	$ 192,006	$ 37,549	$ 487,662	$ 99,631
Product sales
Revenue [Line Items]
Income from continuing operations			231,718	99,191
Licensing revenue
Revenue [Line Items]
Income from continuing operations			255,844	0
Freight revenue
Revenue [Line Items]
Income from continuing operations			$ 100	$ 440

Revenues (Detail Textuals)

Revenues (Detail Textuals)	6 Months Ended
	Feb. 28, 2021USD ($)
Revenues [Abstract]
Usage fees from continuing operations	$ 255,844
Increase In intermediate product sales	$ 231,718

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		6 Months Ended
		Feb. 28, 2021	Feb. 29, 2020
Related Party Transaction [Line Items]
Cash		$ 361,645	$ 339,125
Non-Cash		13,612	187,069
Management, consulting and accounting services		375,257	526,194
C.A.B Financial Services Ltd. ("CAB")
Related Party Transaction [Line Items]
Cash	[1]	136,566	131,557
Non-Cash	[1]	0	0
Management, consulting and accounting services	[1]	136,566	131,557
M&E Services Ltd. ("M&E")
Related Party Transaction [Line Items]
Cash	[1]	62,559	58,785
Non-Cash	[1]	0	0
Management, consulting and accounting services	[1]	62,559	58,785
Docherty Management Limited ("Docherty Management")
Related Party Transaction [Line Items]
Cash	[1]	124,987	113,569
Non-Cash	[1]	0	187,069
Management, consulting and accounting services	[1]	124,987	300,638
Directors
Related Party Transaction [Line Items]
Cash		37,533	35,214
Non-Cash		13,612	0
Management, consulting and accounting services		$ 51,145	$ 35,214
[1]	C.A.B. Financial Services is owned by the CEO of the Company, M&E Services Ltd. is owned by the CFO of the Company, and Docherty Management Limited is owned by the President of the Company.

Related Party Transactions (D_2

Related Party Transactions (Detail Textuals) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Related Party Transaction [Line Items]
Due to related parties	$ 206,806	$ 58,704

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020	Aug. 31, 2020
Revenue	$ 192,006	$ 37,549	$ 487,662	$ 99,631
Cost of goods sold	(30,570)	(58,106)	(95,048)	(65,959)
Operating expenses	256,754	(1,041,119)	(687,545)	(2,020,111)
Discontinued operations	(25,000)	64,184	(22,000)	64,184
Segment income (loss)	393,190	$ (997,492)	(316,931)	$ (1,922,255)
Total assets	12,172,408		12,172,408		$ 2,828,488
IP Licensing
Revenue			255,844
Cost of goods sold			0
Operating expenses			1,142,518
Discontinued operations			(22,000)
Segment income (loss)			1,376,362
Total assets	696,493		696,493
Products
Revenue			231,818
Cost of goods sold			(95,048)
Operating expenses			(278,374)
Discontinued operations			0
Segment income (loss)			141,604
Total assets	137,282		137,282
Corporate
Revenue			0
Cost of goods sold			0
Operating expenses			(1,551,689)
Discontinued operations			0
Segment income (loss)			(1,551,689)
Total assets	$ 11,338,633		$ 11,338,633

Segment Information (Details 1)

Segment Information (Details 1) - USD ($)	6 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Segment Reporting Information [Line Items]
Disposal	$ 3,094
Net Balance	423,205	$ 483,357
US
Segment Reporting Information [Line Items]
Cost	101,144	101,144
Disposal	3,094
Net Balance	74,843	85,263
Canada
Segment Reporting Information [Line Items]
Cost	548,256	548,256
Net Balance	348,362	398,094
Leasehold improvements
Segment Reporting Information [Line Items]
Disposal	0
Net Balance	146,352	173,371
Leasehold improvements | US
Segment Reporting Information [Line Items]
Cost	0	0
Disposal	0
Net Balance	0	0
Leasehold improvements | Canada
Segment Reporting Information [Line Items]
Cost	259,981	259,981
Net Balance	146,352	173,371
Computers
Segment Reporting Information [Line Items]
Disposal	0
Net Balance	22,255	32,095
Computers | US
Segment Reporting Information [Line Items]
Cost	0	0
Disposal	0
Net Balance	0	0
Computers | Canada
Segment Reporting Information [Line Items]
Cost	63,964	63,964
Net Balance	22,255	32,095
Furniture fixtures equipment
Segment Reporting Information [Line Items]
Disposal	3,094
Net Balance	17,914	21,123
Furniture fixtures equipment | US
Segment Reporting Information [Line Items]
Cost	3,094	3,094
Disposal	3,094
Net Balance	0	0
Furniture fixtures equipment | Canada
Segment Reporting Information [Line Items]
Cost	31,126	31,126
Net Balance	17,914	21,123
Lab equipment
Segment Reporting Information [Line Items]
Disposal	0
Net Balance	236,684	256,768
Lab equipment | US
Segment Reporting Information [Line Items]
Cost	98,050	98,050
Disposal	0
Net Balance	74,843	85,263
Lab equipment | Canada
Segment Reporting Information [Line Items]
Cost	193,185	193,185
Net Balance	$ 161,841	$ 171,505

Commitments, Significant Cont_3

Commitments, Significant Contracts and Contingencies Management and Service Agreements (Details)	6 Months Ended
	Feb. 28, 2021CAD ($)
C.A.B Financial Services
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 29,706
Expiry Date	January 1, 2022
Docherty Management Ltd.
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 25,609
Expiry Date	January 1, 2022
M&E Services Ltd.
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 13,997
Expiry Date	June 1, 2021
Office management
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 10,800
Expiry Date	August 15, 2022
Research & development
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 3,854
Expiry Date	Month to Month
Office operating lease
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	$ 4,823	[1]
Expiry Date	November 15, 2023	[1]
[1]	Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. In addition to minimum lease payments, the lease requires us to pay property taxes and operating costs which are subject to annual adjustments.

Commitments, Significant Cont_4

Commitments, Significant Contracts and Contingencies Management and Service Agreements (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Right Of Use Asset [Abstract]
Total right of use assets (February 28, 2021)	$ 109,306	$ 126,920
Liabilities:
Total lease liabilities (February 28, 2021)	107,737
ASC Topic 842, Leases ("ASC 842")
Right Of Use Asset [Abstract]
Additions		118,193
Amortization	(8,887)
Total right of use assets (February 28, 2021)	109,306
Liabilities:
Additions		$ 116,664
Lease payments	(10,987)
Interest accretion	2,061
Total lease liabilities (February 28, 2021)	107,738
Operating cash flows for lease	$ 10,948
Remaining lease term	2 years 6 months
Discount rate	7.25%

Commitments, Significant Cont_5

Commitments, Significant Contracts and Contingencies Management and Service Agreements (Details 2) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
2021	$ 21,975
2022	44,599
2023	44,815
2024	7,469
Thereafter	0
Total lease payments	118,857
Less: imputed interest	(11,119)
Present value of operating lease liabilities	107,737
Less: current obligations under leases	(37,582)	$ (36,038)
Total	$ 70,156	$ 89,393

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Prepaid Expense, Current [Abstract]
Advertising & Conferences	$ 170,165	$ 21,878
Investor relations	71,667	0
Legal fees	0	47,498
Licence, filing fees, dues	59,967	8,541
Office & Insurance	36,561	78,792
Research & Development	25,386	25,386
Prepaid expenses	$ 363,746	$ 182,095

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Marketable Securities [Line Items]
Cost Basis	$ 524,513	$ 56,250
Unrealized Gains	34,407	9,997
Unrealized Losses	(88,288)	(46,926)
Total	470,632	19,321
Common stock
Marketable Securities [Line Items]
Cost Basis	524,513	56,250
Unrealized Gains	24,410	9,997
Unrealized Losses	$ (41,362)	$ (38,584)

Marketable Securities (Detail T

Marketable Securities (Detail Textuals)	Feb. 28, 2021USD ($)
Marketable Securities [Abstract]
Amount of marketable securities	$ 468,263

Discontinued Operations (Detail

Discontinued Operations (Details)	6 Months Ended
	Feb. 28, 2021USD ($)
Gain on asset disposal
Book value of assets sold	$ 0
Cash consideration	273,373
Shares receivable	781,067
Promissory note	0
Gain on asset disposal	$ 1,522,704

Discontinued Operations (Deta_2

Discontinued Operations (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020
Discontinued Operations and Disposal Groups [Abstract]
Revenue			$ 3,000	$ 69,750
Operating Expenses			25,000	5,566
Net Income	$ (25,000)	$ 64,184	$ (22,000)	$ 64,184

Discontinued Operations (Deta_3

Discontinued Operations (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020
Cash flows used in discontinued operating activities
Net income	$ (25,000)	$ 64,184	$ (22,000)	$ 64,184
Change in working capital			105,000	(99,000)
Net cash provided by (used in) discontinued operating activities			83,000	(34,816)
Net cash provided by (used in) discontinued operations			$ 83,000	$ (34,816)

Discontinued Operations (Deta_4

Discontinued Operations (Details 3) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Current Assets
Accounts receivable	$ 0	$ 105,250
Total assets classified as discontinued operations in the consolidated balance sheet	0	105,250
Current Liabilities
Accounts payable	0	250
Total liabilities classified as discontinued operations in the consolidated balance sheet	$ 0	$ 250

Discontinued Operations (Deta_5

Discontinued Operations (Detail Textuals)	1 Months Ended	2 Months Ended
	Nov. 19, 2020CAD ($)	Feb. 10, 2021CAD ($)shares	Dec. 10, 2020$ / shares	Dec. 10, 2020USD ($)
Hill Street Beverage Company Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale non-core business assets		$ 350,000
Restricted common shares received from sale of assets | shares		6,031,363
Deemed price per share | $ / shares			$ 0.0829
10% Promissory note received		$ 2,000,000
Interest rate on promissory note				10.00%
Value of common shares received from sale of assets		1,000,000
Spot rate for conversion of Canadian Dollar				0.78107
Promissory note, nominal value
Hill Street Beverage Company Inc | Sixteen months
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Value of common shares received from sale of assets		500,000
Hill Street Beverage Company Inc | Eight months
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Value of common shares received from sale of assets		$ 500,000
Lexaria Canpharm ULC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale non-core business assets	$ 3,850,000